Investors

We have strong financial and industrial shareholders.

Annual financial statements, quarterly reports and presentations.

Please contact our IR Contacts for any queries.

First Patient Dosed in both the INITIUM and NIPU Phase II Clinical Trials, Testing UV1 Against Metastatic Malignant Melanoma and Mesothelioma (15.06.20)